Mucosat in treatment of osteoarthritis

Abstract

The study included 49 women of average age of 52.4±7.9 years with disease duration of 8.6±5.8 years, at a body mass index of 30.5±4.8 kg/m2. Co-morbidity: previous oncopathology, diabetes, hypertension, obesity. The main symptom was joint pain VAS (100 mm) - 60.2±10.1 mm, index WOMAC pain - 220.7±84.5 mm, WOMAC stiffness - 89.3±39.5, WOMAC function - 726±229.9, WOMAC total - 1036.4±353.9 mm. Mucosat was prescribed intramuscularly. The results were assessed after 3, 8 and 12 weeks on the dynamics of pain (VAS), WOMAC index, in need for NSAID and satisfaction with treatment on a scale from 1 to 5; where '1' is the complete absence of improvement, and '5' is a great result. The control group consisted of 15 OA patients who did not receive hondroprotective treatment for 6 months prior to treatment, received 'on demand' or constantly received NSAIDs. Pain dynamics by VAS and WOMAC index was statistically reliable at 3 week, 8 week and 12 week period of research. 18% of patients stop taking NSAIDs at 3 week, 54% were taking NSAIDs 'on demand' up to 8 weeks. Excellent effect was noted by 42%, good - 22%, low - 8% of patients. Undesirable reactions and side effects were not. The study proved: Mucosat is effective and safe drug for the treatment of OA.